Targeting therapy using chemotherapy-resistant pancreatic cancer stem cells

胰腺导管腺癌对全身化疗具有高度耐药性。他滨耐药胰腺导管腺癌患者。通过与基质细胞体外共培养，建立了一种新的胰腺肿瘤起始细胞系。细胞系的体外克隆生长和传代需要与基质细胞直接相互作用。它们的直接相互作用诱导了基底层样细胞外基质的形成，维持了菌落的形成。该细胞系表达CD133蛋白，其表达水平随培养条件的变化而发生自主变化。这些结果表明，在体外培养耐吉西他滨的胰腺导管腺癌中，存在需要与基质细胞直接相互作用的新型胰腺肿瘤启动细胞。这个细胞系将有助于开发新的治疗方法，增强吉西他滨或新的抗癌药物的效果。

Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. tabine-resistant pancreatic ductal adenocarcinoma patients. By use of in vitro co-culture system with stromal cells, we established a novel pancreatic tumor-initiating cell line. The cell line required its direct interaction with stromal cells for its in vitro clonogenic growth and passaging. Their direct interaction induced basal lamina-like extracellular matrix formation that maintained colony formation. The cell line expressed CD133 protein, which expression level changed autonomously and by culture conditions. These results demonstrated that there were novel pancreatic tumor-initiating cells that required direct interactions with stromal cells for their in vitro cultivation in gemcitabine-resistant pancreatic ductal adenocarcinoma. This cell line would help to develop novel therapies that enhance effects of gemcitabine or novel anti-cancer drugs.